BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23574935)

  • 1. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010.
    Yang YL; Chen HT; Lin CC; Chu WL; Lo HJ;
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):182-6. PubMed ID: 23574935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
    Yang YL; Li SY; Cheng HH; Lo HJ;
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.
    Yang YL; Li SY; Cheng HH; Lo HJ;
    BMC Infect Dis; 2005 Nov; 5():99. PubMed ID: 16266438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
    Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
    Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
    Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010].
    Porte L; León P; Gárate C; Guzmán AM; Labarca J; García P
    Rev Chilena Infectol; 2012 Apr; 29(2):149-55. PubMed ID: 22689028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution and drug susceptibilities of clinical Candida species in TSARY 2014.
    Zhou ZL; Lin CC; Chu WL; Yang YL; Lo HJ;
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):399-404. PubMed ID: 27717650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
    J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis.
    Yang YL; Ho YA; Cheng HH; Ho M; Lo HJ
    Infect Control Hosp Epidemiol; 2004 Jan; 25(1):60-4. PubMed ID: 14756222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.